Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ocifisertib - Treadwell Therapeutics

Next Previous
X
Search
Drug Profile

Ocifisertib - Treadwell Therapeutics

Alternative Names: CFI 400945 fumarate; CFI-400945

Latest Information Update: 28 Jul 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University Health Network
  • Developer AstraZeneca; Canadian Cancer Trials Group; Treadwell Therapeutics; University Health Network
  • Class Antineoplastics; Cyclopropanes; Ethers; Indazoles; Indoles; Morpholines; Small molecules; Spiro compounds
  • Mechanism of Action PLK4 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Breast cancer; Prostate cancer; Triple negative breast cancer
  • Phase I/II Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
  • Preclinical Diffuse large B cell lymphoma
  • No development reported Cancer; Uterine leiomyoma

Most Recent Events

  • 28 Jul 2024 No recent reports of development identified for preclinical development in Uterine-leiomyoma in Canada (PO)
  • 20 Feb 2024 CFI 400945 receives Orphan Drug status for Acute myeloid leukaemia in USA
  • 15 Dec 2023 Efficacy and adverse events data from a phase I/II TWT-202 trial in Acute myeloid leukemia released by Treadwell Therapeutics

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top